Today: 29 June 2026
Browse Category

NASDAQ:ALNY 20 December 2025 - 13 January 2026

Alnylam Pharmaceuticals (ALNY) Stock After Hours: Nasdaq-100 debut, fresh catalysts, and what to watch before Tuesday’s open (Dec. 23)

Alnylam Pharmaceuticals (ALNY) Stock After Hours: Nasdaq-100 debut, fresh catalysts, and what to watch before Tuesday’s open (Dec. 23)

Dec. 22, 2025 — After the closing bell, Alnylam Pharmaceuticals, Inc. is finishing the day in the spotlight for a reason that has nothing to do with a clinical readout—at least not directly. Monday marked the company’s first trading day as a Nasdaq-100 constituent, a mechanical event that can reshape near-term flows even when the underlying business story is unchanged. Here’s what happened in Monday’s session, what the after-hours tape is showing, and the key headlines, forecasts, and risk factors investors are weighing before the market opens Tuesday.
23 December 2025
···
Alnylam Pharmaceuticals (ALNY) Stock on Dec. 22, 2025: Nasdaq-100 Debut, AMVUTTRA Momentum, Analyst Price Targets and the 2026 Outlook

Alnylam Pharmaceuticals (ALNY) Stock on Dec. 22, 2025: Nasdaq-100 Debut, AMVUTTRA Momentum, Analyst Price Targets and the 2026 Outlook

Dec. 22, 2025 — Alnylam Pharmaceuticals, Inc. is stepping into a new tier of market visibility today as its Nasdaq-100 Index membership takes effect ahead of the opening bell—an index catalyst that can influence near-term trading and broaden long-term institutional ownership. Nasdaq+1 ALNY was trading around $405.60 on Dec. 22, up about 1.3% versus the prior close—an incremental move that nonetheless lands in the middle of a busier-than-usual news cycle for the RNAi leader.
22 December 2025
···
Alnylam Pharmaceuticals (ALNY) Stock: Nasdaq-100 Entry, Amvuttra Momentum, Analyst Targets and Key Risks to Know Before the Dec. 22, 2025 Market Open

Alnylam Pharmaceuticals (ALNY) Stock: Nasdaq-100 Entry, Amvuttra Momentum, Analyst Targets and Key Risks to Know Before the Dec. 22, 2025 Market Open

Ahead of the U.S. stock market open on Monday, December 22, 2025, Alnylam Pharmaceuticals, Inc. is stepping into a new spotlight—not just for biotech fundamentals, but also for a major index catalyst that can reshape short-term trading dynamics. As of the most recent close, ALNY last traded around $400.23, within a roughly $220–$500 52-week range.
22 December 2025
···
Alnylam Pharmaceuticals (ALNY) Stock News, Forecasts and Analyst Outlook on Dec. 20, 2025

Alnylam Pharmaceuticals (ALNY) Stock News, Forecasts and Analyst Outlook on Dec. 20, 2025

As of Saturday, December 20, 2025, investors are digesting a busy stretch of developments around Alnylam Pharmaceuticals, Inc.—from Nasdaq-100 index inclusion to fresh reimbursement tailwinds in the U.K. and continued focus on Amvuttra as the company’s main growth engine. Nasdaq+1 Below is a comprehensive roundup of the latest ALNY stock news, forecasts, and market-moving analysis available as of 20.12.2025, plus what to watch next.
20 December 2025
·
Alnylam Pharmaceuticals (ALNY) Stock After Hours: What Happened After the Dec. 19, 2025 Close — and What to Watch Before the Next Market Open

Alnylam Pharmaceuticals (ALNY) Stock After Hours: What Happened After the Dec. 19, 2025 Close — and What to Watch Before the Next Market Open

Alnylam Pharmaceuticals, Inc. finished Friday, December 19, 2025, with shares around $400 and little change in after-hours trading — but the setup into the next U.S. session looks more eventful than the calm “after the bell” tape suggests. ALNY ended the day near $400.23, after trading roughly between the mid-$395s and low-$408s on heavy volume. Investing.com Because December 19 was a Friday, the next U.S. equity market open is Monday, December 22, 2025 — and that date matters for ALNY for one major reason: the Nasdaq-100 index reconstitution takes effect before Monday’s open, and Alnylam is on the add list. Nasdaq+1
20 December 2025
·

Stock Market Today

  • FTSE 100 slips as homebuilders weigh, oil rises
    June 29, 2026, 1:28 PM EDT. The FTSE 100 ended Monday down 0.2% at 10,484.22 as housebuilders and Babcock International slid after the Bank of England reported weak UK mortgage approvals. Brent crude climbed to $72.85 a barrel after fresh US-Iran tensions. Sterling firmed, with Andy Burnham's leadership pitch stressing fiscal discipline, which seemed to calm worries over UK borrowing. European shares edged a bit lower. In contrast, US stocks rose, the S&P 500 up 0.6%. UK mortgage borrowing for May tumbled to £2.9 billion, the lowest in almost two years. US Treasury yields nudged higher. Markets are watching for progress on the oil ceasefire and for news on cabinet jobs in the UK.
Go toTop